R&D

Established in 2013, Rekah’s R&D division has labs with advanced equipment that enable it to develop and license new products.

Our three primary types of R&D projects are:

  • formulating generics
  • developing combination therapeutic entities
  • upgrading dossiers to eCTD format

Our R&D division focuses on two core areas:

  • unique tablets, mainly steroids
  • ophthalmic products